Polymyositis induced by PD-1 blockade in a patient in hepatitis B remission

Cancer cells evade cytotoxic T lymphocyte (CTL)-mediated destruction by taking advantage of a host's negative immune regulators, such as the PD-1 or CTLA-4 signaling pathways. Therefore, immune checkpoint inhibitors (ICIs), which target these pathways, have become a new way of overcoming cancers [1]. PD-1, which is a member of the CD28 family, negatively regulates effector T lymphocyte activation through the interaction with its major ligand, PD-L1 (B7-H1) [2].

Source: Journal of the Neurological Sciences - August 9, 2017 Category: Neurology Authors: Tatsuya Ogawa, Yosuke Ishitsuka, Hanako Koguchi-Yoshioka, Ryota Tanaka, Yasuhiro Fujisawa, Akiko Ishii, Akira Tamaoka, Manabu Fujimoto Tags: Letter to the Editor Source Type: research